HF-158K1 by HighField Biopharmaceuticals for Prostate Cancer: Likelihood of Approval

Galera Ther­a­peu­tics is chop­ping 70% of its staff in the wake of a sting­ing FDA re­jec­tion for its ex­per­i­men­tal treat­ment for a ra­dio­ther­a­py com­pli­ca­tion that

Osteoporosis is the most common metabolic bone disorder worldwide and is the leading cause of fragility fractures. It is a systemic skeletal condition marked by